Common use of Short-Form Prospectus Clause in Contracts

Short-Form Prospectus. The Company has prepared and filed with the British Columbia Securities Commission (the “BCSC”) and the other Canadian provincial securities regulatory authorities other than the Québec Autorité des marchés financiers (the BCSC and such other regulatory authorities, collectively, the “Canadian Commissions”), a preliminary short form base prospectus, dated June 22, 2018, relating to the offering of up to an aggregate amount of U.S. $250,000,000 of Common Shares, preferred shares, debt securities, warrants, subscription receipts and units or any combination thereof (collectively, the “Securities”) and a final short form base shelf prospectus, dated July 5, 2018, in respect of offers and sales, from time to time of the Securities, (together with any documents incorporated therein by reference, and any supplements or amendments thereto (collectively, the “Canadian Base Prospectus”) in accordance with the applicable securities laws of each of the provinces of Canada, other than Québec (the “Qualifying Jurisdictions”), and the respective applicable rules and regulations under such laws, together with applicable published national, multilateral and local instruments, notices and blanket orders in each of the Qualifying Jurisdictions (collectively “Canadian Securities Laws”). The Company has prepared the Canadian Base Prospectus pursuant to National Instrument 44-101—Short Form Prospectus Distributions and NI 44-102 (together, the “Shelf Procedures”). The Company has obtained from the BCSC a receipt for the Canadian Base Prospectus (a “Final Receipt”) and each of the other Canadian Commissions is deemed to have issued a Final Receipt under National Policy 11-202 Process for Prospectus Reviews in Multiple Jurisdictions in respect of the Canadian Base Prospectus.

Appears in 1 contract

Samples: Correvio Pharma Corp.

AutoNDA by SimpleDocs

Short-Form Prospectus. The Company has prepared and filed with the British Columbia Securities Commission (the “BCSC”) and the other Canadian provincial securities regulatory authorities other than the Québec Autorité des marchés financiers (the BCSC and such other regulatory authorities, collectively, the “Canadian Commissions”), a preliminary short form base prospectus, dated June 22February 19, 20182016, relating to the offering of up to an aggregate amount of U.S. $250,000,000 of Common Shares, preferred shares, debt securities, warrants, subscription receipts and units or any combination thereof (collectively, the “Securities”) and a final short form base shelf prospectus, dated July 5March 1, 2018, 2016 in respect of offers and sales, from time to time of the Securities, (together with any documents incorporated therein by reference, and any supplements or amendments thereto (collectively, the “Canadian Base Prospectus”) in accordance with the applicable securities laws of each of the provinces of Canada, other than Québec (the “Qualifying Jurisdictions”), and the respective applicable rules and regulations under such laws, together with applicable published national, multilateral and local policy statements, instruments, notices and blanket orders to the securities regulatory authorities (“Canadian Qualifying Authorities” ) in each of the Qualifying Jurisdictions (collectively “Canadian Securities Laws”). The Company has prepared the Canadian Base Prospectus pursuant to National Instrument 44-101—Short Form Prospectus Distributions and NI 44-102 (together, the “Shelf Procedures”). The Company has obtained from the BCSC a receipt for the Canadian Base Prospectus (a “Final Receipt”) and each of the other Canadian Commissions commissions is deemed to have issued a Final Receipt under National Policy 11-202 Process for Prospectus Reviews in Multiple Jurisdictions in respect of the Canadian Base Prospectus.

Appears in 1 contract

Samples: Cardiome Pharma Corp

Short-Form Prospectus. The Company has prepared and filed with the British Columbia Securities Commission (the “BCSC”) and the other Canadian provincial securities regulatory authorities other than the Québec Autorité des marchés financiers (the BCSC and such other regulatory authorities, collectively, the “Canadian Commissions”), a preliminary short form base shelf prospectus, dated June 22, 2018, relating to the offering of up to an aggregate amount of U.S. $250,000,000 of Common Shares, preferred shares, debt securities, warrants, subscription receipts and units or any combination thereof (collectively, the “Securities”) and a final short form base shelf prospectus, dated July 5, 2018, in respect of offers and sales, from time to time of the Securities, (together with any documents incorporated therein by reference, and any supplements or amendments thereto (collectively, the “Canadian Base Prospectus”) in accordance with the applicable securities laws of each of the provinces of Canada, other than Québec (the “Qualifying Jurisdictions”), and the respective applicable rules and regulations under such laws, together with applicable published national, multilateral and local instruments, notices and blanket orders in each of the Qualifying Jurisdictions (collectively “Canadian Securities Laws”). The Company has prepared the Canadian Base Prospectus pursuant to National Instrument 44-101—Short Form Prospectus Distributions and NI 44-102 (together, the “Shelf Procedures”). The Company has obtained from the BCSC a receipt for the Canadian Base Prospectus (a “Final Receipt”) and each of the other Canadian Commissions is deemed to have issued a Final Receipt under National Policy 11-202 Process for Prospectus Reviews in Multiple Jurisdictions in respect of the Canadian Base Prospectus.

Appears in 1 contract

Samples: Sales Agreement (Correvio Pharma Corp.)

Short-Form Prospectus. The Company has prepared and filed with the British Columbia Securities Commission Autorité des marchés financiers (the “BCSCAMF”) and the other Canadian provincial securities regulatory authorities other than the Québec Autorité des marchés financiers (the BCSC AMF and such other regulatory authorities, collectively, the “Canadian Commissions”), a preliminary short form base shelf prospectus, dated June 22October 11, 20182019, relating to the offering of up to an aggregate amount of U.S. $250,000,000 150,000,000 of Common Shares, preferred shares, debt securities, warrants, subscription receipts and units or any combination thereof (collectively, the “Securities”) and a final short form base shelf prospectus, dated July 5November 15, 20182019, in respect of offers and sales, from time to time of the SecuritiesSecurities together with any subsequent final short form base shelf prospectus, (and together with any documents incorporated therein by reference, and any supplements or amendments thereto (collectively, the “Canadian Base Prospectus”) in accordance with the applicable securities laws of each of the provinces of Canada, other than Québec Canada (the “Qualifying Jurisdictions”), and the respective applicable rules and regulations under such laws, together with applicable published national, multilateral and local instruments, notices and blanket orders in each of the Qualifying Jurisdictions (collectively “Canadian Securities Laws”). The Company has prepared the Canadian Base Prospectus pursuant to National Instrument 44-101—Short Form Prospectus Distributions (“NI 44-101”) and NI 44-102 (together, the “Shelf Procedures”). The Company has obtained from the BCSC AMF a receipt for the Canadian Base Prospectus (a “Final Receipt”) and each of the other Canadian Commissions is deemed to have issued a Final Receipt under National Policy 11-202 Process for Prospectus Reviews in Multiple Jurisdictions in respect of the Canadian Base Prospectus.

Appears in 1 contract

Samples: Sales Agreement (Theratechnologies Inc.)

AutoNDA by SimpleDocs

Short-Form Prospectus. The Company has prepared and filed with the British Columbia Securities Commission (the “BCSC”) and the other Canadian provincial securities regulatory authorities other than the Québec Autorité des marchés financiers (the BCSC and such other regulatory authorities, collectively, the “Canadian Commissions”), a preliminary short form base prospectus, dated June 22January 29, 2018, 2014. relating to the offering of up to an aggregate amount of U.S. $250,000,000 of Common Shares, preferred shares, debt securities, warrants, subscription receipts and units warrants or any combination thereof (collectively, the “Securities”) and a final short form base shelf prospectus, dated July 5February 13, 2018, 2014 in respect of offers and sales, from time to time of the Securities, (together with any documents incorporated therein by reference, and any supplements or amendments thereto (collectively, the “Canadian Base Prospectus”) in accordance with the applicable securities laws of each of the provinces of Canada, other than Québec (the “Qualifying Jurisdictions”), and the respective applicable rules and regulations under such laws, together with applicable published national, multilateral and local policy statements, instruments, notices and blanket orders to the securities regulatory authorities (“Canadian Qualifying Authorities” ) in each of the Qualifying Jurisdictions (collectively “Canadian Securities Laws”). The Company has prepared the Canadian Base Prospectus pursuant to National Instrument 44-101—Short Form Prospectus Distributions and NI 44-102 (together, the “Shelf Procedures”). The Company has obtained from the BCSC a receipt for the Canadian Base Prospectus (a “Final Receipt”) and each of the other Canadian Commissions commissions is deemed to have issued a Final Receipt under National Policy 11-202 Process for Prospectus Reviews in Multiple Jurisdictions in respect of the Canadian Base Prospectus.

Appears in 1 contract

Samples: Cardiome Pharma Corp

Short-Form Prospectus. The Company has prepared and filed a preliminary short form base shelf prospectus dated December 18, 2017 in the English language (the “Canadian Preliminary Base Prospectus”) with the British Columbia Ontario Securities Commission (the “BCSCOSC”) and with the other Canadian provincial securities commissions or other securities regulatory authorities other than in each of the Québec Autorité des marchés financiers provinces in Canada (the BCSC and such other regulatory authorities, collectively, the “Canadian Securities Commissions”), a preliminary short form base prospectus, dated June 22, 2018, relating to the offering ) in respect of up to an aggregate amount of U.S. $250,000,000 of Common Shares, preferred shares, debt various securities, warrants, subscription receipts and units or any combination thereof including preferred shares (collectively, the “Securities”), in accordance with the applicable Canadian Securities Laws (as defined below) and (ii) has prepared and filed with the Canadian Securities Commissions a final (final) short form base shelf prospectusprospectus dated January 4, dated July 5, 2018, in respect of offers and sales, from time 2018 relating to time of the Securities, (together the “Canadian Final Base Prospectus”). The Company has prepared the Canadian Base Prospectus (as defined below) pursuant to National Instrument 44-101—Short Form Prospectus Distributions and National Instrument 44-102— Shelf Distributions (together, the “Shelf Procedures”). The Company selected the OSC as its principal regulator in respect of the Canadian Preliminary Base Prospectus and Canadian Final Base Prospectus, and the OSC has issued a receipt (a “Receipt”) in accordance with any Multilateral Instrument 11-102—Passport System and National Policy 11-202—Process for Prospectus Reviews in Multiple Jurisdictions on behalf of itself and the other applicable Canadian Securities Commissions for the Canadian Final Base Prospectus. The term “Canadian Base Prospectus” means the Canadian Final Base Prospectus, including documents incorporated therein by reference, and any supplements or amendments at the time the Receipt was issued with respect thereto (collectively, the “Canadian Base Prospectus”) in accordance with Canadian Securities Laws, including the applicable Shelf Procedures. The term “Canadian Securities Laws” means securities laws of each of the provinces of Canada, other than Québec (the “Qualifying Jurisdictions”), Canada and the respective applicable rules and regulations under such laws, together with applicable published national, multilateral and local policy statements, instruments, notices and blanket orders in each of the Qualifying Jurisdictions (collectively “Canadian Securities Laws”). The Company has prepared the Canadian Base Prospectus pursuant to National Instrument 44-101—Short Form Prospectus Distributions and NI 44-102 (together, the “Shelf Procedures”). The Company has obtained from the BCSC a receipt for the Canadian Base Prospectus (a “Final Receipt”) and each of the other Canadian Commissions is deemed to have issued a Final Receipt under National Policy 11-202 Process for Prospectus Reviews in Multiple Jurisdictions in respect of the Canadian Base ProspectusSecurities Commissions.

Appears in 1 contract

Samples: Original Agreement (Just Energy Group Inc.)

Time is Money Join Law Insider Premium to draft better contracts faster.